Germany-based Boehringer Ingelheim has agreed to buy a facility for biotech drug development and manufacturing in Fremont, CA owned by Amgen (NASDAQ: AMGN). The 100,000 square foot facility, where about 360 people work, is expected to formally be handed over to Boehringer Ingelheim before the end of March, the companies said. Terms of the deal weren’t disclosed. Amgen obtained the facility through its $2.2 billion acquisition of Abgenix in 2006. The biotech giant said it plans to maintain a presence in the Bay Area through its South San Francisco facility.